Evinova & Harbour BioMed Partner on AI-Enabled Drug Development
Yesterday, in the course of the eighth China International Import Expo (“CIIE”), Evinova, a worldwide health-tech firm accelerating the supply of higher well being outcomes by propelling the life sciences sector ahead in digital well being, and Harbour BioMed (HKEX: 02142), a worldwide biopharmaceutical firm dedicated to the invention and improvement of novel antibody therapeutics in immunology and oncology, introduced a strategic collaboration in synthetic intelligence (AI).
Under the phrases of the collaboration, Evinova China and Harbour BioMed will collectively apply AI and digital applied sciences to reinforce the effectivity of modern biologics improvement. Building on their very own strengths, the 2 corporations intention to construct an open ecosystem for AI-driven drug R&D.
Nate Zhang, General Manager of Evinova China, said, “Evinova leverages the digital transformation insights of high world pharmaceutical corporations to design our AI-powered medical improvement options and digital technique consulting providers, in order that we are able to speed up the supply of higher well being outcomes. To notice our mission, Evinova China must associate with modern corporations like Harbour BioMed, that are rooted in China whereas harboring world ambitions. Together, by way of our world-class AI expertise platforms and deep therapeutic experience, we might help take China-originated breakthrough belongings from the laboratory to the world.”
Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed, said, “We are happy to collaborate with Evinova to advance the applying of AI in biotherapeutic improvement. Harbour BioMed has constructed a sturdy and differentiated product pipeline primarily based on our industry-leading Harbour Mice® expertise platform. Through this collaboration, we sit up for making use of AI to bettering medical examine effectivity and accelerating the supply of modern therapies to sufferers world wide.”
The publish Evinova & Harbour BioMed Partner on AI-Enabled Drug Development first appeared on AI-Tech Park.
